Connect your AI

Anika Therapeutics ANIK Debt-to-assets

Debt-to-assets at other companies

StrykerSYK

0.3×-0.1×

VericelVCEL

0.2×0.0×

Zimmer Biomet HoldingsZBH

0.3×0.0×

Pacira BioSciences, Inc.PCRX

0.3×+0.1×

BioventusBVS

0.4×-0.1×

Xtant Medical HoldingsXTNT

0.2×0.0×

Other financials

Income statement

Revenue$29.6M+13.2%

Net income-$5.1M-3.8%

Balance sheet

Cash & equivalents$41.0M-23.1%

Total debt$25.7M+1.2%

Total equity$133.9M-9.8%

Total assets$179.4M-5.9%

Cash flow

Operating cash flow-$4.8M-3,628%

CapEx$1.4M-49.3%

Free cash flow-$6.3M-112%

Valuation

Market cap$204.37M+31.6%

Enterprise value$189.09M+48.7%

P/S1.8×+0.1×

Profitability

Net margin-9.8%-4.4pp

FCF margin0.9%—

Returns & leverage

Return on equity-8%-3.4pp

Debt / equity0.2×0.0×

Current ratio4.5×-1.3×

Where this comes from

Calculated from Anika Therapeutics’s reported figures.

total debt/total assets=0.1×

Based on the most recent quarter.

The official record: Anika Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Anika Therapeutics's debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Anika Therapeutics's debt-to-assets?: Anika Therapeutics (ANIK) reported debt-to-assets of 0.1× in Q1 2026.
How has Anika Therapeutics's debt-to-assets changed year-over-year?: Anika Therapeutics's debt-to-assets increased by 7.5% year-over-year, from 0.1× to 0.1×.
What is the long-term trend for Anika Therapeutics's debt-to-assets?: Over 5 years (2020 to 2025), Anika Therapeutics's debt-to-assets has grown at a 17.7% compound annual growth rate (CAGR), from 0.1× to 0.1×.
What does debt-to-assets mean?: Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.